Liver Regenerative Medicine & Hepatocyte Cell Therapy Market
完整報告名稱與涵蓋範圍
Liver Regenerative Medicine & Hepatocyte Cell Therapy Market Size, Share & Trends Analysis Report, By Therapy Type (Primary and Cryopreserved Hepatocyte Cell Therapies, Stem Cell-Derived Hepatocyte and Liver Progenitor Therapies, Bioartificial Liver and Extracorporeal Support Systems, Regenerative Small Molecules and Biologics), By Indication (Acute Liver Failure and Acute-on-Chronic Liver Failure, Inherited Metabolic Liver Diseases, Cirrhosis and End-Stage Liver Disease, Bridging to Transplant), By Development Stage (Preclinical and Early Clinical, Late-Stage Clinical, Commercial and Hospital-Exemption Products), By End User, By Region, and Segment Forecasts, 2026-2035
報告摘要
The liver regenerative medicine and hepatocyte cell therapy market covers therapies that restore liver function by transplanting primary or stem cell-derived hepatocytes and progenitor cells, growing ectopic liver tissue, supporting patients with bioartificial liver systems or stimulating endogenous regeneration with biologics and small molecules, across acute liver failure, inherited metabolic liver diseases and end-stage liver disease. Whole-organ transplantation, conventional liver drugs and research-use hepatocyte products are excluded. Most therapeutic revenue is contingent on clinical progression and is modelled from trial timelines; current revenue derives from hospital-exemption products, early commercial cell products and clinical supply.
The unmet need is stark: liver transplantation is constrained by donor supply, and patients with acute liver failure or metabolic disorders often die waiting. Allogeneic hepatocyte and liver-derived progenitor cell products have shown safety and signals of benefit in pediatric metabolic disease and acute-on-chronic liver failure, ectopic liver organoid approaches have entered human trials, and induced pluripotent stem cell-derived hepatocytes are approaching clinical readiness. Manufacturing scale, cell engraftment, immunosuppression requirements and endpoint selection are the principal development hurdles, while regenerative biologics face the same trial-design challenges that confront antifibrotic drugs.
Europe and the United States host most developers and trial sites, with Japan and South Korea active in stem cell-derived approaches. The competitive field is small, combining cell therapy specialists, regenerative biotechnology companies and pharmaceutical partners.
The InsightAce study provides US$ revenue forecasts for every therapy type, indication, development stage and end user and regional segment over 2026-2035, plus segment trend analysis, competitive landscape mapping and profiles of leading participants.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Liver Regenerative Medicine & Hepatocyte Cell Therapy Market Snapshot
Chapter 4. Global Liver Regenerative Medicine & Hepatocyte Cell Therapy Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Therapy Type Estimates & Trend Analysis
5.1. Therapy Type & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Therapy Type:
5.2.1. Primary and Cryopreserved Hepatocyte Cell Therapies
5.2.2. Stem Cell-Derived Hepatocyte and Liver Progenitor Therapies
5.2.3. Bioartificial Liver and Extracorporeal Support Systems
5.2.4. Regenerative Small Molecules and Biologics
Chapter 6. Market Segmentation 2: By Indication Estimates & Trend Analysis
6.1. Indication & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Indication:
6.2.1. Acute Liver Failure and Acute-on-Chronic Liver Failure
6.2.2. Inherited Metabolic Liver Diseases
6.2.3. Cirrhosis and End-Stage Liver Disease
6.2.4. Bridging to Transplant
Chapter 7. Market Segmentation 3: By Development Stage Estimates & Trend Analysis
7.1. Development Stage & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Development Stage:
7.2.1. Preclinical and Early Clinical
7.2.2. Late-Stage Clinical
7.2.3. Commercial and Hospital-Exemption Products
Chapter 8. Market Segmentation 4: By End User Estimates & Trend Analysis
8.1. End User & Market Share, 2026 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by End User:
8.2.1. Transplant and Hepatology Centers
8.2.2. Pediatric Hospitals
8.2.3. Research Institutes
Chapter 9. Liver Regenerative Medicine & Hepatocyte Cell Therapy Market: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. United States
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. South Korea
9.3.5. Australia
9.3.6. Southeast Asia
9.3.7. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. GCC Countries
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Landscape
10.1. Company Market Positioning Analysis
10.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 11. Company Profiles
11.1. Promethera Biosciences (Cellaion)
11.2. Yposkesi (SK pharmteco)
11.3. Ambys Medicines, Inc.
11.4. Satellite Bio, Inc.
11.5. LyGenesis, Inc.
11.6. Takeda Pharmaceutical Company Limited
11.7. Vital Therapies (Legacy ELAD Program)
11.8. HepaRegeniX GmbH
11.9. Cynata Therapeutics Limited
11.10. Novo Nordisk A/S
11.11. BioIVT (Hepatocyte Supply)
11.12. Lonza Group AG (Hepatocyte Products)
11.13. Fujifilm Cellular Dynamics, Inc.
11.14. Regenerative Medical Technology Group
11.15. Genenta Science S.p.A.
圖表清單 List of Tables & Figures
Table 1. Global Liver Regenerative Medicine & Hepatocyte Cell Therapy Market Revenue Forecast by Therapy Type, 2026-2035 (US$ Mn)
Figure 1. Global Liver Regenerative Medicine & Hepatocyte Cell Therapy Market Segmentation Overview
Table 2. Global Liver Regenerative Medicine & Hepatocyte Cell Therapy Market Revenue Forecast by Indication, 2026-2035 (US$ Mn)
Figure 2. Global Liver Regenerative Medicine & Hepatocyte Cell Therapy Market Share by Therapy Type, 2026 & 2035
Table 3. Global Liver Regenerative Medicine & Hepatocyte Cell Therapy Market Revenue Forecast by Development Stage, 2026-2035 (US$ Mn)
Figure 3. Liver Regenerative Approaches from Cell Transplantation to Ectopic Organoids and Bioartificial Support
Table 4. Global Liver Regenerative Medicine & Hepatocyte Cell Therapy Market Revenue Forecast by End User, 2026-2035 (US$ Mn)
Figure 4. Global Liver Regenerative Medicine & Hepatocyte Cell Therapy Market Share by Indication, 2026 & 2035
Table 5. North America Liver Regenerative Medicine & Hepatocyte Cell Therapy Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 5. Clinical Pipeline by Indication, Cell Source and Phase, 2026
Table 6. Europe Liver Regenerative Medicine & Hepatocyte Cell Therapy Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Asia Pacific Liver Regenerative Medicine & Hepatocyte Cell Therapy Growth Opportunity Analysis
Table 7. Asia Pacific Liver Regenerative Medicine & Hepatocyte Cell Therapy Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Donor Organ Shortage Versus Addressable Patient Populations for Regenerative Therapies
Table 8. Latin America Liver Regenerative Medicine & Hepatocyte Cell Therapy Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 8. Competitive Positioning of Key Liver Regenerative Medicine & Hepatocyte Cell Therapy Market Participants
Table 9. Middle East & Africa Liver Regenerative Medicine & Hepatocyte Cell Therapy Market Revenue by Country, 2026-2035 (US$ Mn)
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們